The in vitro activities of 12 macrolide compounds against 28 Mycobacterium avium complex strains isolated from patients with acquired immunodeficiency syndrome were determined by the conventional proportion method and by the BACTEC method. Clarithromycin (A-56268; TE-031), a new macrolide compound, was the most active agent tested, inhibiting 90% of strains at an MIC of 4 ,ug/ml by the BACTEC method. Roxithromycin (RU 28965) and erythromycylamine inhibited 90% of strains at 16 ,ug/ml. The organisms showed high levels of resistance to most other macrolide compounds.
The in vitro activities of 12 macrolide compounds against 28 Mycobacterium avium complex (MAC) strains isolated from patients with acquired immunodeficiency syndrome were determined by the conventional proportion method and by the BACTEC method. Clarithromycin (A-56268; TE-031), a new macrolide compound, was the most active agent tested, inhibiting 90% of strains at an MIC of 4 ,ug/ml by the BACTEC method. Roxithromycin (RU 28965) and erythromycylamine were active at an MIC of 16 ,ug/ml for 90% of strains. The organism showed high levels of resistance to most other macrolide compounds. Infection caused by MAC organism is difficult to treat because the organism is resistant to multiple drugs (6, 9) . With the increasing incidence of MAC infection in patients with acquired immunodeficiency syndrome, the search for effective therapy with newer drugs is significant (18; H. Masur, Editorial, J. Am. Med. Assoc. 248:3013, 1982). Macrolide antibiotics are relatively nontoxic and are used against a wide variety of gram-positivebacterial infections. Erythromycin is the agent most commonly used against many gram-positive organisms, such as Streptococcus pneumoniae and Legionella spp. (7) . Its activity against mycobacteria has not been well studied. It produces gastrointestinal discomfort in some patients and is unstable in gastric juices (P. B. Fernandes, Antimicrob. Newsl. 4:25-34, 1987) .
Recently, several new macrolide antibiotics structurally related to erythromycin have been studied by several research groups (1, 3, 13) . Preliminary reports suggest that some of these compounds have favorable pharmacological properties and that they are well tolerated (7; Fernandes, Antimicrob. Newsl. 4:25-34, 1987 ). Owing to exceptional pharmacokinetic qualities, a therapeutic dose could be much lower than for a classical macrolide. Our study was designed to assess the in vitro activities of some of the newer macrolides, along with erythromycin, against MAC.
The in vitro susceptibilities of MAC strains were determined with the routine agar dilution (indirect susceptibility) test by using the proportion method (4, 11) and with the BACTEC rapid radiometric system (Becton Dickinson, Baltimore, Md.), whose results have been reported by others (12, (14) (15) (16) (17) . Specifically, this system has been used successfully with MAC by several workers (8, 10) . Isolates were obtained from patients with acquired immunodeficiency syn-* Corresponding author. drome, as well as from referral cultures submitted to the New York State Health Department for identification and drug susceptibility testing. All strains were identified by using standard criteria. Transparent colonies were preserved in skim milk at -20°C. The strains were grown in Middlebrook 7H9 broth for 2 to 4 days before the susceptibility studies were done.
The indirect drug susceptibility test was performed by using the conventional proportion method (11) . Different concentrations (0.25 to 64 ,ug/ml) of 12 macrolide drugs were added to Middlebrook 7H11 agar. Each culture (McFarland standard no. 1) was diluted up to 10-5; the 10-' dilution was used as the inoculum, and the 10-5 dilution was used as the control. The agar slants were incubated at 37°C for 14 to 21 days, and the amount of growth was noted. The lowest concentration that inhibited more than 99% of the bacterial population was considered the MIC determined by this method. The vials were incubated at 37°C and read daily to note the change in growth index.
For MIC determinations by the radiometric method, 0.1 ml of a 10-2 dilution (in BACTEC diluent fluid) of McFarland standard no. 1 was inoculated in BACTEC vials containing various concentrations (0.25 to 64 pug/ml) of drugs, and a plain vial inoculated with 0.1 ml of a 10-4 dilution was used as the control. The lowest concentration of drug which produced a daily growth index increase no greater than that in the 1:100 control was considered the radiometric MIC (8) .
The antibiotics used in this study and their sources were as follows: roxithromycin, Hoechst-Roussel Pharmaceuticals, 0.25 to 4 ,ug/ml). Roxithromycin and erythromycylamine showed moderate activity (MIC for 50% of strains tested, 8 ,ug/ml).
Although there were a few discrepancies between the two methods in MICs of some macrolide compounds, at higher drug concentrations (.16 pug/ml) the discrepancies were inapparent. Table 2 shows an analysis of two methods of drug susceptibility testing. A ratio of the MIC of the proportion method to that of the radiometric method equal to unity indicates that both methods produced the same results. More than 50% of the strains tested (MIC, <32 ,ug/ml) had a ratio equal to unity. A ratio of 2 indicates that the proportion method MIC was double that of the radiometric method. The percentages of strains in this category (3 to 42%) varied with the type of drug. Few strains with a ratio of more than 2 were found. Considering the dilution error of one log2, the discrepancies between the two methods are not major. In our 23-Demycinosyltylosin (8, 10) : binding of the drug in solid medium, deterioration of the drug owing to the prolonged incubation period, and rather crude evaluation of the result in the proportional method, suggesting that the radiometric method is superior. The radiometric system is rapid and reliable. The cell-to-drug interaction is three dimensional, and the results obtained are in semiquantifiable units. However, the system is relatively expensive and laborious. The problem of radioactive-waste disposal is also involved.
Our data regarding the in vitro activities of many of the newer macrolides are in general close to those reported by other investigators (2, 5) . Although clarithromycin, a new macrolide, demonstrated excellent in vitro activity against all MAC isolates tested, clinical experience with this agent is lacking. Preliminary studies indicate that clarithromycin is well absorbed when administered orally and consistently attains levels of 2 ,ug/ml in blood at a dose of 400 mg and 4. 
